Naringin sensitizes human prostate cancer cells to paclitaxel therapy

Basit Öğe Kaydı
dc.authoridhttp://orcid.org/0000-0002-1365-9897en_US
dc.contributor.authorErdogan, Suat
dc.contributor.authorDoganlar, Oguzhan
dc.contributor.authorDoganlar, Zeynep B.
dc.contributor.authorTurkekul, Kader
dc.date.accessioned2019-06-25T12:08:58Z
dc.date.available2019-06-25T12:08:58Z
dc.date.issued2018
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyoloji Anabilim Dalıen_US
dc.descriptionErdogan, Suat (Trakya author) Doganlar, Oguzhan (Trakya author) Doganlar, Zeynep B. (Trakya author) Turkekul, Kader (Trakya author)en_US
dc.description.abstractBackground: The aim of the study was to evaluate whether the use of chemotherapy in combination with naringin, a dietary plant polyphenolic flavonoid, could enhance the therapeutic efficacy of paclitaxel treatment in human prostate cancer (PCa) cells. Materials and methods: DU145, PC3, and LNCaP cells were treated with various concentrations of paclitaxel, naringin, and their combinations. Methylthiazolyldiphenyl-tetrazolium bromide (MTT), image-based cytometer, quantitative reverse transcription PCR (RT-qPCR), Western blot, and transwell assay were used to evaluate cell viability, apoptosis and cell cycle, the mRNA expression, protein expression, and cell migration, respectively. Results: Naringin treatment inhibited cell survival in a dose- and time-dependent manner by inducing apoptosis and cell cycle arrest in G1 phase. Among the pathways evaluated, naringin (150 mu M) significantly induced the mRNA expressions of BAX, BID, caspase 3, cytochrome c, p53, p21(Cip1), and p27(Kip1) and down-regulated the expressions of survivin and livin in DU145 cells. The combination of naringin and paclitaxel treatments synergistically increased the cytotoxic effects of paclitaxel in androgen-independent DU145 and PC3 cells, as well as in androgen-sensitive LNCaP cells. The combination of naringin with docetaxel has almost the same inhibitory effect on cell proliferation as the paclitaxel combination in androgen-independent cells, whereas there is no similar effect in LNCaP cells. Naringin exhibits significant inhibitory effects on the cell migration ability. The flavonoid either alone or in combination with paclitaxel therapy resulted in an increase in tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) protein expression and decrease in nuclear factor-kB p50 protein level in DU145 cells. Conclusion: In conclusion, naringin acts as a chemosensitizer which synergistically strengths the cytotoxic effect of paclitaxel in PCa cells. Therefore, naringin therapy alone or in combination with paclitaxel may be useful in the treatment of PCa. However, there is a need for more detailed in vivo studies of the mechanism of action. (C) 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC.en_US
dc.identifier.citationErdogan, S., Doganlar, O., Doganlar, Z. B., & Turkekul, K. (2018). Naringin sensitizes human prostate cancer cells to paclitaxel therapy. Prostate International, 6(4), 126-135.en_US
dc.identifier.doi10.1016/j.prnil.2017.11.001en_US
dc.identifier.endpage135en_US
dc.identifier.issue4en_US
dc.identifier.pmid30505814en_US
dc.identifier.scopus2-s2.0-85039050298en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage126en_US
dc.identifier.urihttps://doi.org/10.1016/j.prnil.2017.11.001
dc.identifier.urihttps://hdl.handle.net/20.500.14551/4219
dc.identifier.volume6en_US
dc.identifier.wosWOS:000451160700002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb fo Sciencesen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofProstate Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240608_ID_Qen_US
dc.subjectApoptosisen_US
dc.subjectCell Migrationen_US
dc.subjectChemotherapyen_US
dc.subjectNaringinen_US
dc.subjectProstate Canceren_US
dc.titleNaringin sensitizes human prostate cancer cells to paclitaxel therapyen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu